<DOC>
	<DOCNO>NCT02855775</DOCNO>
	<brief_summary>This Study evaluate covariables able potentially influence elimination monoclonal antibody ( trastuzumab , bevacizumab denosumab ) .</brief_summary>
	<brief_title>Monoclonal Antibodies Elimination Breast Cancer Patient</brief_title>
	<detailed_description>Monoclonal antibody widely use cancer treatment . Certain patient benefit antibody several year conceivable wonder evolution pharmacokinetics antibody .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>A diagnosed cancer patient treat bevacizumab trastuzumab Life expectancy least 3 month For woman : menopausal woman least 24 month , sterilize surgically , , woman old enough procreate , use method effective contraception ( oral contraceptive , contraceptive injection , intrauterine device , method double barrier , contraceptive patch ) . This contraception pursue 6 month end treatment bevacizumab trastuzumab . For Patients treated trastuzumab : Dyspnoea severe rest touch complication due disease require oxygen therapy . Hypocalcemia severe untreated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>